5 completed, 1 recruiting. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow LTX-315: new trials by email Literature Review of LTX-315 trials Research Report on LTX-315
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma LTX-315 + pembrolizumab - Melanoma Stage IIIB-IV | Phase 2 | Recruiting | Oslo University Hospital | 27 | 2024-11-01 | 2024-10-26 |
| Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma LTX-315 in combination with pembrolizumab - Advanced Melanoma | Phase 2 | Completed | Lytix Biopharma AS | 23 | 2021-11-05 | 2026-09-10 |
| LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04) LTX-315 and TILs - Soft Tissue Sarcoma | Phase 2 | Completed | Lytix Biopharma AS | 6 | 2018-12-28 | 2025-12-05 |
| LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab LTX-315 consecutive lesions, LTX-315, LTX-315 + ipilimumab - Cancer, Melanoma | Phase 1 | Completed | Lytix Biopharma AS | 80 | 2013-11-01 | 2018-10-03 |
| A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma LTX-315 - Carcinoma | Phase 1 | Completed | Lytix Biopharma AS | 12 | 2010-08-01 | 2012-01-11 |
| Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour LTX-315 (Oncopore™) - Cancer With Transdermal Accessible Tumour | Phase 1 | Completed | Lytix Biopharma AS | 14 | 2010-01-01 | 2013-02-11 |
Melanoma (3) · Neoplasms (2) · Breast Neoplasms (1) · Carcinoma (1) · Head and Neck Neoplasms (1) · Lymphoma (1) · Sarcoma (1) · Triple Negative Breast Neoplasms (1)
Lytix Biopharma AS (5) · Oslo University Hospital (1)
Norway (5) · France (2) · Belgium (1) · Denmark (1) · Italy (1) · Spain (1) · Sweden (1) · United Kingdom (1) · United States (1)
Inge Marie Svane, MD (1) · James Spicer, MD, PhD (1) · Oystein Rekdal, PHD (1) · Paal Brunsvig, MD, PhD (1)
PMID 31177991, PMID 33542073, PMID 38125722
2023 (1)